Clinical Trials · NCT01731925
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Enrollment
- 44
- Start date
- Jan 2013
- Locations
- 20 sites, Belgium, France
- Primary endpoint
- Progression free survival (PFS)